TN2009000294A1 - Compounds and compositions as channel activating protease inhibitors - Google Patents
Compounds and compositions as channel activating protease inhibitorsInfo
- Publication number
- TN2009000294A1 TN2009000294A1 TNP2009000294A TN2009000294A TN2009000294A1 TN 2009000294 A1 TN2009000294 A1 TN 2009000294A1 TN P2009000294 A TNP2009000294 A TN P2009000294A TN 2009000294 A TN2009000294 A TN 2009000294A TN 2009000294 A1 TN2009000294 A1 TN 2009000294A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds
- channel activating
- compositions
- protease inhibitors
- activating protease
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 abstract 3
- 102100032471 Transmembrane protease serine 4 Human genes 0.000 abstract 3
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 abstract 2
- 102100022046 Brain-specific serine protease 4 Human genes 0.000 abstract 1
- 108010059081 Cathepsin A Proteins 0.000 abstract 1
- 102000005572 Cathepsin A Human genes 0.000 abstract 1
- 101000897856 Homo sapiens Adenylyl cyclase-associated protein 2 Proteins 0.000 abstract 1
- 101000896891 Homo sapiens Brain-specific serine protease 4 Proteins 0.000 abstract 1
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 abstract 1
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 abstract 1
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 abstract 1
- 101000598054 Homo sapiens Transmembrane protease serine 11B Proteins 0.000 abstract 1
- 101000637855 Homo sapiens Transmembrane protease serine 11E Proteins 0.000 abstract 1
- 101000798707 Homo sapiens Transmembrane protease serine 13 Proteins 0.000 abstract 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 abstract 1
- 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 abstract 1
- 108010028275 Leukocyte Elastase Proteins 0.000 abstract 1
- 108010091175 Matriptase Proteins 0.000 abstract 1
- 101100069392 Mus musculus Gzma gene Proteins 0.000 abstract 1
- 102100033174 Neutrophil elastase Human genes 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 102100029500 Prostasin Human genes 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 102100037023 Transmembrane protease serine 11B Human genes 0.000 abstract 1
- 102100032001 Transmembrane protease serine 11E Human genes 0.000 abstract 1
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 abstract 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 abstract 1
- 108090000631 Trypsin Proteins 0.000 abstract 1
- 102000004142 Trypsin Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108010031970 prostasin Proteins 0.000 abstract 1
- 239000012588 trypsin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88433407P | 2007-01-10 | 2007-01-10 | |
| US89147407P | 2007-02-23 | 2007-02-23 | |
| PCT/US2007/085366 WO2008085608A1 (fr) | 2007-01-10 | 2007-11-21 | Composés et compositions en tant qu'inhibiteurs de protéases activatrices de canaux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2009000294A1 true TN2009000294A1 (en) | 2010-12-31 |
Family
ID=39148650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2009000294A TN2009000294A1 (en) | 2007-01-10 | 2009-07-08 | Compounds and compositions as channel activating protease inhibitors |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080176901A1 (fr) |
| EP (2) | EP2279777A2 (fr) |
| JP (1) | JP2010515729A (fr) |
| KR (1) | KR101084787B1 (fr) |
| AR (1) | AR064841A1 (fr) |
| AT (1) | ATE493174T1 (fr) |
| AU (1) | AU2007342223B2 (fr) |
| BR (1) | BRPI0720799A2 (fr) |
| CA (1) | CA2673803A1 (fr) |
| CL (1) | CL2008000060A1 (fr) |
| CO (1) | CO6190626A2 (fr) |
| CU (1) | CU23762B7 (fr) |
| CY (1) | CY1111340T1 (fr) |
| DE (1) | DE602007011670D1 (fr) |
| DK (1) | DK2104535T3 (fr) |
| EA (1) | EA016199B1 (fr) |
| EC (1) | ECSP099517A (fr) |
| GT (1) | GT200900196A (fr) |
| HN (1) | HN2009001282A (fr) |
| HR (1) | HRP20110201T1 (fr) |
| MA (1) | MA31037B1 (fr) |
| MX (1) | MX2009007476A (fr) |
| NO (1) | NO20092817L (fr) |
| NZ (1) | NZ577939A (fr) |
| PE (1) | PE20081566A1 (fr) |
| PL (1) | PL2104535T3 (fr) |
| PT (1) | PT2104535E (fr) |
| RS (1) | RS51644B (fr) |
| SV (1) | SV2009003330A (fr) |
| TN (1) | TN2009000294A1 (fr) |
| TW (1) | TW200845981A (fr) |
| WO (1) | WO2008085608A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2419626C2 (ru) | 2006-05-23 | 2011-05-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| KR101132577B1 (ko) | 2007-01-10 | 2012-04-05 | 에프. 호프만-라 로슈 아게 | 키마아제 억제제로서의 술폰아미드 유도체 |
| CA2677487A1 (fr) | 2007-02-09 | 2008-08-14 | Irm Llc | Composes et compositions servant d'inhibiteurs de protease d'activation de canaux |
| AR076880A1 (es) | 2009-05-18 | 2011-07-13 | Orion Corp | Inhibidores de proteasa, composiciones farmaceuticas que los contienen y su uso. |
| US10399940B2 (en) * | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| GB201805174D0 (en) * | 2018-03-29 | 2018-05-16 | Univ Leeds Innovations Ltd | Compounds |
| CN112867706B (zh) | 2018-05-29 | 2024-11-15 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| BR112021018456A2 (pt) * | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| US20220354833A1 (en) | 2019-09-17 | 2022-11-10 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
| CN115103709A (zh) | 2019-12-04 | 2022-09-23 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| CN115052604A (zh) | 2019-12-04 | 2022-09-13 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| AU2020395306B2 (en) * | 2019-12-04 | 2025-04-24 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP7721143B2 (ja) | 2019-12-04 | 2025-08-12 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| LT4106757T (lt) | 2020-04-16 | 2023-11-10 | Mereo Biopharma 4 Limited | Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui |
| AU2022373971A1 (en) | 2021-10-20 | 2024-04-04 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
| WO2023183405A2 (fr) * | 2022-03-22 | 2023-09-28 | Alexion Pharmaceuticals, Inc. | Composés pharmaceutiques pour le traitement de troubles médiés par le complément |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| US5605923A (en) | 1992-04-02 | 1997-02-25 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| AU677776B2 (en) | 1992-04-02 | 1997-05-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
| US5707966A (en) * | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
| ZA951617B (en) * | 1994-03-04 | 1997-02-27 | Lilly Co Eli | Antithrombotic agents. |
| US5726159A (en) * | 1994-03-04 | 1998-03-10 | Eli Lilly And Company | Antithrombotic agents |
| US5705487A (en) * | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
| US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
| GB2299455B (en) * | 1995-03-31 | 1999-12-22 | Motorola Inc | Self phased antenna element with dielectric and associated method |
| AU3496297A (en) * | 1996-06-25 | 1998-01-14 | Eli Lilly And Company | Anticoagulant agents |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| WO2000000531A1 (fr) | 1998-06-30 | 2000-01-06 | The Dow Chemical Company | Polymeres et leur procede de production |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| CZ20013940A3 (cs) | 1999-05-04 | 2002-04-17 | Schering Corporation | Piperazinové deriváty uľitečné jako CCR5 antagonisté |
| TR200103213T2 (tr) | 1999-05-04 | 2002-03-21 | Schering Corporation | CCR5 antagonistleri olarak yararlì piperidin trevleri. |
| US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| BRPI0013478B8 (pt) | 1999-08-21 | 2016-12-27 | Altana Pharma Ag | medicamento compreendendo inibidor pde e uso de roflumilast |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| JP2003533448A (ja) | 2000-04-27 | 2003-11-11 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規持続性ベータ擬似剤、その製造方法及びその医薬としての使用 |
| UA72632C2 (uk) | 2000-06-27 | 2005-03-15 | Лабораторіос С.А.Л.В.А.Т., С.А. | Карбамати, похідні від арилалкіламінів |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| ES2523930T3 (es) | 2000-08-05 | 2014-12-02 | Glaxo Group Limited | Éster s-fluorometílico del ácido 6-alfa,9-alfa-difluoro-17-alfa-[(2-furanilcarbonil)oxi]-11-beta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dien-17-carbotioico como agente antiinflamatorio |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| KR100869722B1 (ko) | 2000-12-22 | 2008-11-21 | 알미랄 에이쥐 | 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용 |
| DK1353919T3 (da) | 2000-12-28 | 2006-11-20 | Almirall Prodesfarma Ag | Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| PT1383786E (pt) | 2001-04-30 | 2008-12-30 | Glaxo Group Ltd | Derivados anti-inflamatórios de éster 17.beta-carbotioato de androstano com um grupo éster ciclíco na posição 17.alfa |
| US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| JP4405258B2 (ja) | 2001-06-21 | 2010-01-27 | ヴェレニウム コーポレイション | ニトリラーゼ |
| WO2003013571A1 (fr) * | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetiques de metallopeptides biologiquement actifs |
| DK1425001T3 (da) | 2001-09-14 | 2009-04-14 | Glaxo Group Ltd | Phenethanolaminderivater til behandling af respiratoriske sygdomme |
| RU2004110717A (ru) | 2001-10-17 | 2005-10-20 | Юсиби, С.А. (Be) | Производные хинуклидина, способы их получения и их применение в качестве и нгибиторов м2- и/или м3- мускариновых рецепторов |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
| WO2003048181A1 (fr) | 2001-12-01 | 2003-06-12 | Glaxo Group Limited | 17.alpha.-esters cycliques de 16-methylpregnan-3,20-dione en tant qu'agents anti-inflammatoires |
| UA76571C2 (en) | 2001-12-20 | 2006-08-15 | Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor | |
| WO2003072592A1 (fr) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17 alpha esters cycloalkyle/cycloalcenyle d'alkyle ou haloalkyle-androst-4-en-3-on-11 beta, 17 alpha-diol 17 beta-carboxylates comme agents anti-inflammatoires |
| WO2003062259A2 (fr) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Nouveaux composes |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| WO2003082787A1 (fr) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations |
| ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
| JP4570878B2 (ja) | 2002-04-11 | 2010-10-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的糖質コルチコイド受容体モジュレーターとしての１Ｈ−ベンゾ［ｆ］インダゾール−５−イル誘導体 |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ATE381535T1 (de) | 2002-04-25 | 2008-01-15 | Glaxo Group Ltd | Phenethanolaminderivate |
| JP2005527618A (ja) | 2002-05-28 | 2005-09-15 | セラヴァンス インコーポレーテッド | アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| EP1517895B1 (fr) | 2002-06-25 | 2007-03-14 | Merck Frosst Canada Ltd. | Inhibiteurs de pde4 8-(biaryle)quinolines |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| AU2003281219A1 (en) | 2002-07-02 | 2004-01-23 | Bernard Cote | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| MXPA05000345A (es) | 2002-07-08 | 2005-03-31 | Pfizer Prod Inc | Moduladores del receptor de glucocorticoides. |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| ES2286491T3 (es) | 2002-08-10 | 2007-12-01 | Nycomed Gmbh | Piperidina-ftalazonas sustituidas con pirrolidinadiona, como agentes inhibidores de la pde4. |
| HRP20050197A2 (en) | 2002-08-10 | 2006-06-30 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| JP2005538138A (ja) | 2002-08-10 | 2005-12-15 | アルタナ ファルマ アクチエンゲゼルシャフト | Ｐｄｅ４インヒビターとしてのピリダジノン誘導体 |
| RS20050116A (sr) | 2002-08-17 | 2007-11-15 | Altana Pharma Ag., | Novi fenantridini |
| HRP20050227A2 (en) | 2002-08-17 | 2006-06-30 | Altana Pharma Ag | Novel benzonaphthyridines |
| CA2496175A1 (fr) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| US7288562B2 (en) | 2002-08-23 | 2007-10-30 | Ranbaxy Laboratories Limited | Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists |
| JP4619786B2 (ja) | 2002-08-29 | 2011-01-26 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性、アレルギー性及び増殖性疾患の治療において糖質コルチコイドミメティックスとして使用するための３−（スルホンアミドエチル）−インドール誘導体 |
| CA2496459C (fr) | 2002-08-29 | 2013-06-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridines en tant qu'inhibiteurs de pde-4 |
| EP1539164B1 (fr) | 2002-08-29 | 2006-12-20 | ALTANA Pharma AG | 2-hydroxy-6-phenylphenanthridines utilisees comme inhibiteurs de pde-4 |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| MXPA05002771A (es) | 2002-09-18 | 2005-06-06 | Ono Pharmaceutical Co | Derivados de triazaspiro [5.5] undecano y farmacos que comprenden los mismos como el ingrediente activo. |
| AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| ATE392206T1 (de) | 2002-10-11 | 2008-05-15 | Pfizer | Indolderivate als beta-2 agonisten |
| EP1440966A1 (fr) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Dérivés d'indole utilisables pour traiter des maladies |
| DE60315492T2 (de) | 2002-10-22 | 2008-04-24 | Glaxo Group Ltd., Greenford | Medizinisch verwendbare arylethanolamin verbindungen |
| CN100532374C (zh) | 2002-10-23 | 2009-08-26 | 格兰马克药品有限公司 | 可用于治疗炎性和变应性病症的新的三环化合物:它们的制备方法以及包含它们的药物组合物 |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| EP1556342B1 (fr) | 2002-10-28 | 2008-03-26 | Glaxo Group Limited | Derive de phenethanolamine utilise dans le traitement de maladies respiratoires |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| US7019019B2 (en) * | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
| CA2512987C (fr) | 2003-01-21 | 2011-06-14 | Merck & Co., Inc. | Derives cortisol de 17-carbamoyloxy utilises en tant que modulateurs selectifs des recepteurs aux glucocorticoides |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1460064A1 (fr) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Derivés de Indole-2-carboxamide comme beta-2 agonistes |
| GB0507577D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-21 NZ NZ577939A patent/NZ577939A/en not_active IP Right Cessation
- 2007-11-21 AU AU2007342223A patent/AU2007342223B2/en not_active Ceased
- 2007-11-21 HR HR20110201T patent/HRP20110201T1/hr unknown
- 2007-11-21 JP JP2009545545A patent/JP2010515729A/ja not_active Ceased
- 2007-11-21 EP EP10013675A patent/EP2279777A2/fr not_active Withdrawn
- 2007-11-21 EA EA200900920A patent/EA016199B1/ru not_active IP Right Cessation
- 2007-11-21 PL PL07854747T patent/PL2104535T3/pl unknown
- 2007-11-21 KR KR1020097014455A patent/KR101084787B1/ko not_active Expired - Fee Related
- 2007-11-21 US US11/943,845 patent/US20080176901A1/en not_active Abandoned
- 2007-11-21 WO PCT/US2007/085366 patent/WO2008085608A1/fr not_active Ceased
- 2007-11-21 EP EP07854747A patent/EP2104535B9/fr active Active
- 2007-11-21 AT AT07854747T patent/ATE493174T1/de active
- 2007-11-21 RS RS20110129A patent/RS51644B/sr unknown
- 2007-11-21 DK DK07854747.8T patent/DK2104535T3/da active
- 2007-11-21 MX MX2009007476A patent/MX2009007476A/es active IP Right Grant
- 2007-11-21 BR BRPI0720799-9A patent/BRPI0720799A2/pt not_active IP Right Cessation
- 2007-11-21 CA CA002673803A patent/CA2673803A1/fr not_active Abandoned
- 2007-11-21 DE DE602007011670T patent/DE602007011670D1/de active Active
- 2007-11-21 PT PT07854747T patent/PT2104535E/pt unknown
-
2008
- 2008-01-10 TW TW097101044A patent/TW200845981A/zh unknown
- 2008-01-10 CL CL200800060A patent/CL2008000060A1/es unknown
- 2008-01-10 AR ARP080100104A patent/AR064841A1/es not_active Application Discontinuation
- 2008-01-10 PE PE2008000105A patent/PE20081566A1/es not_active Application Discontinuation
-
2009
- 2009-06-30 MA MA32060A patent/MA31037B1/fr unknown
- 2009-07-08 TN TNP2009000294A patent/TN2009000294A1/fr unknown
- 2009-07-08 HN HN2009001282A patent/HN2009001282A/es unknown
- 2009-07-08 GT GT200900196A patent/GT200900196A/es unknown
- 2009-07-10 CU CU20090122A patent/CU23762B7/es not_active IP Right Cessation
- 2009-07-10 SV SV2009003330A patent/SV2009003330A/es not_active Application Discontinuation
- 2009-07-13 CO CO09072488A patent/CO6190626A2/es not_active Application Discontinuation
- 2009-07-15 EC EC2009009517A patent/ECSP099517A/es unknown
- 2009-08-10 NO NO20092817A patent/NO20092817L/no not_active Application Discontinuation
-
2011
- 2011-03-14 CY CY20111100283T patent/CY1111340T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000294A1 (en) | Compounds and compositions as channel activating protease inhibitors | |
| MX2009008493A (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal. | |
| MX2009008518A (es) | Compuestos y composiciones como inhibidores de la proteasa activadora de canal. | |
| WO2007137080A3 (fr) | Composés et compositions en tant qu'inhibiteurs de protéases activatrices de canal | |
| WO2007079096A3 (fr) | Inhibition de protéase | |
| SE0201980D0 (sv) | Novel compounds | |
| MX2010008523A (es) | Inhibidores macrociclicos de serina proteasa. | |
| SE0201976D0 (sv) | Novel compounds | |
| IL183308A0 (en) | Cathepsin cysteine protease inhibitors | |
| GB2393656B (en) | Enzyme-sensitive therapeutic wound dressings | |
| WO2008042480A3 (fr) | Inhibiteurs époxyde de cystéine protéases | |
| NO20075370L (no) | Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer | |
| SE0201977D0 (sv) | Novel compounds | |
| MXPA05008240A (es) | Inhibidores de catepsina s. | |
| UY30629A1 (es) | Nuevo péptido de actinomadura namibiensis | |
| DK1292673T3 (da) | Trombomodulinanaloger til farmaceutisk anvendelse | |
| SE0203712D0 (sv) | Novel compounds | |
| MX2008002493A (es) | Composicion farmaceutica solida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph. | |
| SI1729794T1 (sl) | Farmacevtski pripravek, ki vsebuje sulfobetain, ki nima lastnosti detergenta | |
| UA95502C2 (ru) | Соединения и композиция как ингибиторы активирующей каналы протеазы | |
| TW200510436A (en) | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | |
| DK1603584T3 (da) | Aplidine til behandling af multipelt myelom | |
| ATE518878T1 (de) | Antimikrobielle peptide | |
| TW200721245A (en) | Pump apparatus for semiconductor processing | |
| WO2003028621A3 (fr) | Inhibiteurs de proteinase utilises dans le traitement et le diagnostic de maladies neurodegeneratives |